Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 4 Liposarcoma 2 Leiomyosarcoma 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neoplasms 1 Neoplasm Metastasis 1 Histiocytoma, Malignant Fibrous 1 Hemangiosarcoma 1 Gastrointestinal Stromal Tumors 1 Dermatofibrosarcoma 1 Chordoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Merkel Cell 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1

Interventions

Doxorubicin 18 Ifosfamide 13 Radiotherapy 8 Paclitaxel 7 pazopanib 6 pembrolizumab 4 Gemcitabine 4 Filgrastim 4 Chemotherapy, Adjuvant 4 Bevacizumab 4 spartalizumab 3 durvalumab 3 Sorafenib 3 Propranolol 3 Nivolumab 3 Ipilimumab 3 Imatinib Mesylate 3 Etoposide 3 Epirubicin 3 Docetaxel 3 Carboplatin 3 trebananib 2 regorafenib 2 cixutumumab 2 cemiplimab 2 carotuximab 2 brostallicin 2 belinostat 2 balstilimab 2 Watchful Waiting 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Hemangiosarcoma × avelumab × Sarcoma × Clear all

NCT03512834 2018-07-11

ASAP

Dong-A University Hospital

Phase 2 Unknown

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡